Skip to main content
. 2024 Feb 1;18:306–321. doi: 10.1016/j.xjon.2024.01.014

Figure E4.

Figure E4

A, Interleukin 6 (IL-6) expression with increasing losartan (H441, ∗P = .001; H358, ∗P = .000; H1299, ∗P = .000; SW1573, ∗P = .000; TC-1, ∗P = .000). B, Program death ligand 1 (PD-L1) expression with increasing losartan (H441, ∗P = .000; H358, ∗P = .000; H1299, ∗P = .043; SW1573, ∗P = .000; TC-1, ∗P = .020). C, Program death ligand 2 (PD-L2) expression with increasing losartan (H441, ∗P = .012; H358, ∗P = .000; H1299, ∗P = .001; SW1573, ∗P = .002; TC-1, ∗P = .000). D, IL-6 expression with increasing losartan and losartan combined cisplatin (H441, ∗P = .032, #P = .0.044; H358, ∗P = .021, #P = .025; H1299, ∗P = .042, #P = .042; SW1573, ∗P = .033, #P = .036; TC-1, ∗P = .001, #P = .013). E, PD-L1 expression with increasing losartan and combined cisplatin (H441, ∗P = .000, #P = .000; H358, ∗P = .000, #P = .023; H1299, ∗P = .000, #P = .000; SW1573, ∗P = .000, #P = .000; TC-1, ∗P = .005, #P = .007). F, PD-L2 expression with increasing losartan and combined with cisplatin (H441, ∗P = .000, #P = .000; H358, ∗P = .002, #P = .002; H1299, ∗P = .001, #P = .008; SW1573, ∗P = .046, #P = .033; TC-1, ∗P = .004, #P = .011).